A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)

Outcome Description:

AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.

Outcome Time Frame:

Baseline up to Week 144

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4001050

NCT ID:

NCT00426660

Start Date:

February 2007

Completion Date:

June 2010

Related Keywords:

• Advanced HIV Infection
• HIV Infections
• HIV Infections
• Acquired Immunodeficiency Syndrome